Strategic pivot SeqOnce has transitioned from direct in-house development to having its technologies adopted and commercialized by companies within the G3 Genomics portfolio. This suggests potential partnerships or channel opportunities with Bandit Bio and other portfolio firms for cross-sell of reagents, kits, and related tools.

Recent product The July 2025 RT-qPCR Measles Panel launch indicates continuing expansion of diagnostic capabilities. This creates upsell opportunities for additional pathogen panels, multiplex assays, and companion controls to labs expanding infectious disease testing.

Geographic growth Expansion to Carlsbad, California in 2023 signals a footprint in a major biotech hub. Target near-market collaborations with local contract research organizations, academic labs, and biotechs to leverage convenient support, training, and service needs.

Historical portfolio Past launches in RT-qPCR and NGS library prep kits demonstrate expertise across core molecular workflows. Approach potential buyers with bundled workflows and validated kits that integrate sequencing prep with diagnostic assays to streamline lab pipelines.

Financial and scale Revenue is in the small-to-mid range with modest funding, indicating a potential fit for strategic partnerships, co-development deals, or pilot programs with larger genomics players seeking nimble collaboration, faster time-to-market, and lower upfront risk.